Tolerogenic Synthetic Nanocarriers - Patent EP3682877A1
Summary
The European Patent Office granted Patent EP3682877A1 to Cartesian Therapeutics, Inc. covering tolerogenic synthetic nanocarriers for therapeutic applications. The patent protects compositions and methods relating to synthetic nanoparticle carriers designed to induce immune tolerance. The designation covers 35 European contracting states including Germany, France, the United Kingdom, Italy, and Spain.
What changed
The European Patent Office published Patent EP3682877A1 granting Cartesian Therapeutics, Inc. exclusive rights to tolerogenic synthetic nanocarrier compositions and methods. The patent, classified under IPC categories including A61K 9/16, A61K 47/30, and B82Y 5/00, covers synthetic nanoparticle delivery systems designed to induce immune tolerance for therapeutic purposes.
For pharmaceutical manufacturers and biotechnology companies developing nanocarrier-based therapeutics, this patent establishes intellectual property barriers in the European market. Companies pursuing tolerogenic nanoparticle programs for autoimmune diseases, allergies, or transplant applications should evaluate potential licensing needs or design-around strategies to avoid infringement claims in designated contracting states.
What to do next
- Monitor for infringement of EP3682877A1 nanocarrier technology
- Review freedom-to-operate for related therapeutic nanocarrier products
- Consider patent portfolio strategy in European markets
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TOLEROGENIC SYNTHETIC NANOCARRIERS
Publication EP3682877A1 Kind: A1 Apr 01, 2026
Applicants
Cartesian Therapeutics, Inc.
Inventors
FRASER, Christopher, ROY, Christopher J., LIPFORD, Grayson B., MALDONADO, Roberto A.
IPC Classifications
A61K 31/445 20060101AFI20200525BHEP A61K 39/38 20060101ALI20200525BHEP A61K 39/395 20060101ALI20200525BHEP A61K 9/16 20060101ALI20200525BHEP A61K 9/14 20060101ALI20200525BHEP A61K 47/30 20060101ALI20200525BHEP A61P 29/00 20060101ALI20200525BHEP A61K 31/00 20060101ALI20200525BHEP A61K 39/36 20060101ALI20200525BHEP B82Y 5/00 20110101ALI20200525BHEP A61K 39/00 20060101ALI20200525BHEP A61K 47/50 20170101ALI20200525BHEP A61K 47/52 20170101ALI20200525BHEP A61K 47/54 20170101ALI20200525BHEP A61K 47/59 20170101ALI20200525BHEP A61K 9/127 20060101ALI20200525BHEP A61K 9/51 20060101ALI20200525BHEP A61K 38/13 20060101ALI20200525BHEP A61K 38/18 20060101ALI20200525BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.